ACELYRIN, INC. Common Stock (SLRN) Stock
SLRN is no longer traded. ACELYRIN, INC. Common Stock was delisted from the Nasdaq in May 2025.
Prices on this page are historical; the last trade was May 20, 2025 at $2.27.
ACELYRIN, INC. Common Stock stock price history
SLRN final trading statistics
- Final close
- $2.27
- Final trading day
- May 20, 2025
- Market cap at delisting
- $229.17M
- Shares outstanding
- 100.95M
- Final 52-week range
- $1.84 – $7.25
- Avg. volume (final 3 mo.)
- 1,475,987
- All-time high (split-adj.)
- $28.82 · Aug 2023
- All-time low (split-adj.)
- $1.89 · Feb 2025
- Return since IPO
- -90.3%
- Beta
- 1.09
- Book value / share
- $4.04
- Price / book
- 0.56
ACELYRIN, INC. Common Stock annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $0.00 | -$248.2M | -$2.50 |
| FY2023 | $0.00 | -$381.6M | -$4.35 |
| FY2022 | $0.00 | -$250.5M | — |
| FY2021 | $0.00 | -$41.8M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About ACELYRIN, INC. Common Stock
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED). Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California. As of May 21, 2025, Acelyrin, Inc. operates as a subsidiary of Alumis Inc.
ACELYRIN, INC. Common Stock stock FAQ
What happened to ACELYRIN, INC. Common Stock stock?
ACELYRIN, INC. Common Stock stock was delisted from the Nasdaq. Its final close was $2.27 on May 20, 2025.
Is SLRN stock still trading?
No. SLRN was delisted from the Nasdaq in May 2025 and no longer trades on a U.S. exchange.
What was the last price of SLRN stock?
SLRN closed at $2.27 on its final trading day, May 20, 2025, for a market value of about $229.17M.
What were ACELYRIN, INC. Common Stock's revenue and earnings in its last full fiscal year?
ACELYRIN, INC. Common Stock reported revenue of $0.00 and net income of -$248.2M in fiscal 2024, its last full year as a public company.
When did ACELYRIN, INC. Common Stock go public?
ACELYRIN, INC. Common Stock stock began trading on May 4, 2023.